Cargando…

Effect of the IL-1 Receptor Antagonist Kineret(®) on Disease Phenotype in mdx Mice

Duchenne muscular dystrophy (DMD) is an X-linked muscle disease caused by mutations in the dystrophin gene. The pathology of DMD manifests in patients with progressive muscle weakness, loss of ambulation and ultimately death. One of the characteristics of DMD is muscle inflammation, and dystrophin-d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benny Klimek, Margaret E., Sali, Arpana, Rayavarapu, Sree, Van der Meulen, Jack H., Nagaraju, Kanneboyina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877010/ https://www.ncbi.nlm.nih.gov/pubmed/27213537 http://dx.doi.org/10.1371/journal.pone.0155944

Ejemplares similares

The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
por: Sali, Arpana, et al.
Publicado: (2013)

Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype
por: Rayavarapu, Sree, et al.
Publicado: (2010)

IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse
por: Kostek, Matthew C, et al.
Publicado: (2012)

Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
por: Coley, William, et al.
Publicado: (2013)

Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse
por: Sali, Arpana, et al.
Publicado: (2012)

Non-invasive Optical Imaging of Muscle Pathology in mdx Mice Using Cathepsin Caged Near-Infrared Imaging
por: Baudy, Andreas R., et al.
Publicado: (2010)

Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy(2J) Mouse Model of Congenital Muscular Dystrophy
por: Yu, Qing, et al.
Publicado: (2013)

Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies
por: Coley, William, et al.
Publicado: (2012)

Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice
por: Quinn, James L, et al.
Publicado: (2013)

Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice
por: Spurney, Christopher F, et al.
Publicado: (2011)

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
por: Rayavarapu, Sree, et al.
Publicado: (2013)

Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model
por: Jahnke, Vanessa E, et al.
Publicado: (2012)

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse
por: Zhang, Aiping, et al.
Publicado: (2015)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
por: Kaiser, Christina, et al.
Publicado: (2011)

Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits
por: Heier, Christopher R., et al.
Publicado: (2014)

Kineret(®)/IL-1ra Blocks the IL-1/IL-8 Inflammatory Cascade during Recombinant Panton Valentine Leukocidin-Triggered Pneumonia but Not during S. aureus Infection
por: Labrousse, Delphine, et al.
Publicado: (2014)

Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
por: Echigoya, Yusuke, et al.
Publicado: (2015)

Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia
por: Duddy, William, et al.
Publicado: (2015)

Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005)

Tempol treatment shows phenotype improvement in mdx mice
por: Hermes, Túlio de Almeida, et al.
Publicado: (2019)

Greater Colo-Rectal Activation Phenotype in Exercised mdx Mice
por: Nearing, Marie, et al.
Publicado: (2018)

Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein
por: Mâncio, Rafael Dias, et al.
Publicado: (2017)

Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne
por: Thangarajh, Mathula, et al.
Publicado: (2019)

The FVB Background Does Not Dramatically Alter the Dystrophic Phenotype of Mdx Mice
por: Wasala, Nalinda B., et al.
Publicado: (2015)

Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice
por: Pelosi, Laura, et al.
Publicado: (2015)

Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy
por: Capogrosso, Roberta Francesca, et al.
Publicado: (2018)

“Of Mice and Measures”: A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic: First Workshop Report: Examining current findings and opportunities around the emerging D2.B10-Dmd(mdx)/J (D2/mdx) model in context of the classic C57BL/10ScSn-Dmd(mdx)/J (Bl10/mdx)
por: Gordish-Dressman, Heather, et al.
Publicado: (2018)

Short-Term ONX-0914 Administration: Performance and Muscle Phenotype in Mdx Mice
por: Kwak, Dongmin, et al.
Publicado: (2020)

Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice
por: Nogami, Ken'ichiro, et al.
Publicado: (2021)

Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse
por: Spurney, Christopher F., et al.
Publicado: (2010)

Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret(®)) in systemic juvenile idiopathic arthritis
por: Livermore, P, et al.
Publicado: (2008)

PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
por: Wikén, M, et al.
Publicado: (2013)

Hormonal Receptors in Skeletal Muscles of Dystrophic Mdx Mice
por: Feder, David, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1drgtc5c46bek29fqmvtmmn1rv